// App-Quantinova.ai

: Nonacog beta pegol (N9‐GP) for prophylaxis in children with hemophilia B: up to 3.5‐year data from the paradigm™5 clinical trial

Researchers

Presenter

  • E. Santagostino

Principal Investigators

  • S. Kearney

  • M. Carcao

  • F. Abdul Karim

  • M. Taki

  • M.-Y. Lu

  • M.-L. Garly

  • M. Zak

Medical Centers

  • Angelo Bianchi Bonomi Haemophilia andThrombosis Center. IRCCS Ca Granda Foundation,Maggiore Hospital, Milan, Italy

  • Children's Hospitals and Clinics of Minnesota Hemophilia and Thrombosis Center, Minneapolis, MN, USA

  • Division of Haematology/Oncology, Department of Paediatrics and Research Institute, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

  • Haemophilia Center, National Blood Centre, Kuala Lumpur, Malaysia

  • Department of Pharmacy, St.Marianna University School of Medicine, Kawasaki, Japan

  • National Taiwan University Hospital, Children's and Women's Hospital, Taipei, China

  • Novo NordiskA/S, Soborg, Denmark

Locations

  • Italy

  • United States

  • Canada

  • Malaysia

  • Japan

  • China

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Bayer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved